European Leukemia Trial Registry
Trial: SPARK-AML1

More Details
Title Randomized Study of AZD1152 Alone and in Combination With LDAC in Comparison With LDAC Alone in de novo AML
Scientific Title A Randomised, Open-label, Multi-centre, 2-stage, Parallel Group Study to Assess the Efficacy, Safety and Tolerability of AZD1152 Alone and in Combination With Low Dose Cytosine Arabinoside (LDAC) in Comparison With LDAC Alone in Patients Aged ≥ 60 With Newly Diagnosed Acute Myeloid Leukaemia (AML)
Short Title SPARK-AML1
Trialgroup NN
Type of Trial multicentric, randomized, open-label
Disease Acute myeloid leukemia(AML) AML all subtypes without FAB M3
Age >= 60 years
Status No longer recruiting
Start of Recruitment 04.08.2009
Leader Stockman, Paul
Shortprotocol Shortprotocol
created 15.07.2010 Johannes Kraus
changed 01.06.2015 Hanna Ebert
ELIC European Leukemia Information Center | no responsibility is taken for correctness and completeness of this information | www.leukemia-net.org | elic@leukemia-net.org